L&B Cellomics

L&B Cellomics

The CELLOMICS platform specialises in providing stem cell-based cell culture systems and customer-specific services for neurological disease modelling and compound development. Our areas of competence encompass the generation of induced pluripotent stem cells (iPS cells), neural iPS cell differentiation and customer-specific cell production and assay development. The CELLOMICS platform has acknowledged expertise in the development of human stem cell-based model systems and their industrialisation at its disposal (Terstegge et al., 2007; Koch et al., 2009; Falk et al., 2012; Koch et al., 2011; Haupt et al., 2012; Mertens et al., 2013; Elanzew et al., 2015). Proprietary technologies make it possible to generate pure, cryopreservable neural, neuronal and glial cells. from pure, cryopreservable populations. Through our close collaboration with the outstanding scientists at the Institute of Reconstructive Neurobiology and as part of a large number of national and EU-wide research projects, we systematically implement innovative stem cell-based technologies and optimise these technologies for biomedical applications on an industrial scale. Our competence in the field of cell biology is complemented by many years’ experience in co-development with leading manufacturers for laboratory automation.

Our services encompass the following areas:

Induced Pluripotent Stem Cells

In collaboration with the GENOMICS platform, we provide comprehensive solutions for iPS cell generation, expansion and quality control for research projects. Together with our academic partner, the IRN (the Institute of Reconstructive Neurobiology at the University of Bonn), iPS cells can be recruited from a diverse range of neurological disease backgrounds.

The platform has implemented a range of robust differentiation protocols for generating cryopreservable, neural and glial cell populations derived from iPS cells (Koch et al., 2009; Gorres et al., 2015).

  • lt-NES® cells
  • sensory neurons
  • dopaminergic neurons
  • cortical neurons
  • astrocytes
  • oligodendrocytes

Using healthy and disease-specific iPS cell lines, we develop phenotypic assays together with our clients for use in disease research and drug discovery. Based on established differentiation protocols, we provide the adaptation and optimisation of cell production and quality controls for assay development (Koch et al. 2011; Schwenk et al., 2016; Seidel et al 2016; Stacey et al. 2016).

The CELLOMICS platform has been using automated cell culture systems for human stem cell cultures for over 10 years (Terstegge et al., 2007, Terstegge et al., 2010; Haupt et al 2012; Elanzew et al., 2015). Today, the CELLOMICS platform operates a fully automated system for generating and expanding human iPS cells. The system was developed together with partners from the fields of engineering and life sciences (http://www.stemcellfactory3.de). Based on our many years of experience in this field and our biological expertise, we offer consultancy services for automated stem cell-based production processes. In addition, we are able to develop individual concepts for process automation and their technical implementation by utilising our interdisciplinary network.

Since 2015, the CELLOMICS platform has been a contractual partner with the pharmaceutical industry driven French-German Translational Research Center (KSILINK).

The CELLOMICS platform uses a wide-ranging academic and industrial network in order to develop its research work, services and products. Alongside its own laboratory capacity, the CELLOMICS platform has access to a diverse range of technologies and resources – for example in the fields of laboratory automation (Hamilton Robotics, Automated Lab Solutions), production technology (Fraunhofer IPT), drug development (div. Pharma) and project management (P3 Group) through its wide cooperation network of leading research institutes and companies. Furthermore, CELLOMICS cooperates closely with scientists from the Institute of Reconstructive Neurobiology to efficiently translate the latest findings from near basic stem cell research into commercial use.

back to Overview